ESMO 2022 | Current biomarker testing guidelines for colorectal cancer

John Strickler, MD, Duke Cancer Center, Durham, NC, provides an overview of standard biomarker testing guidelines in the United States for colorectal cancer. Clinicians often look for KRAS, NRAS, BRAF and HER2 mutations and whilst HER2 mutations may not benefit from EFGR inhibitors, off-label HER2 inhibitors may benefit for patients with HER2 mutations. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3ZWhLDH

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.